Mosanna Therapeutics raises €70.1M to disrupt sleep apnea treatment with nasal spray
Mosanna Therapeutics, a biotech company specialised in the treatment of obstructive sleep apnea (OSA), has secured $80M (approximately €70.1M) in Series A funding. The financing was led by Pivotal bioVenture Partners and EQT Life Sciences, along with Forbion, Broadview Ventures, and Norwest as co-lead investors. Returning investors included founding investor Forty51 Ventures as well as
Mosanna Therapeutics raises €70.1M to disrupt sleep apnea treatment with nasal spray Read More »